Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
76 studies found for:    "Multiple Sclerosis, Chronic Progressive"
Show Display Options
RSS Create an RSS feed from your search for:
"Multiple Sclerosis, Chronic Progressive"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Lipoic Acid for Secondary Progressive Multiple Sclerosis (MS)
Condition: Multiple Sclerosis, Chronic Progressive
Interventions: Drug: lipoic acid;   Drug: Placebo
2 Completed Efficacy of Cyclophosphamide Versus Methylprednisolone in Patients With Secondary Progressive Multiple Sclerosis
Condition: Multiple Sclerosis, Chronic Progressive
Interventions: Drug: Cyclophosphamide (drug);   Drug: Methylprednisolone (drug)
3 Unknown  Safety Study of RTL1000 (Recombinant T Cell Receptor Ligand) in Subjects With Multiple Sclerosis
Conditions: Multiple Sclerosis, Chronic Progressive;   Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: RTL1000 (recombinant T cell receptor ligand);   Drug: RTL1000 Placebo
4 Not yet recruiting Tolerogenic Dendritic Cells as a Therapeutic Strategy for the Treatment of Multiple Sclerosis Patients (TOLERVIT-MS)
Conditions: Multiple Sclerosis, Relapsing-Remitting;   Multiple Sclerosis, Chronic Progressive
Interventions: Drug: Autologous VitD3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides (tolDC-VitD3);   Drug: Interferon-beta
5 Completed Use on Human Beings of Mix of Known Drugs for New Destination - MS Treatment
Conditions: Multiple Sclerosis;   Autoimmune Disease;   Disseminated or Multiple Sclerosis Nos;   Multiple Sclerosis, Acute Relapsing;   Multiple Sclerosis, Primary Progressive;   Multiple Sclerosis, Chronic Progressive
Interventions: Drug: Tetracycline;   Drug: statin;   Drug: antimycotic;   Drug: Fingolimod;   Drug: copaxone
6 Temporarily not available Use of Well Known Drugs for New Destination - MS Improvement (MSNT)
Conditions: Multiple Sclerosis;   Autoimmune Diseases;   Disseminated or Multiple Sclerosis Nos;   Multiple Sclerosis, Acute Relapsing;   Multiple Sclerosis, Primary Progressive;   Multiple Sclerosis, Chronic Progressive
Intervention: Drug: Tetracycline - Statin - Antimycotic
7 Recruiting Intrathecal Rituximab in Progressive Multiple Sclerosis
Conditions: Multiple Sclerosis, Chronic Progressive;   Nervous System Diseases
Interventions: Drug: Rituximab IT;   Drug: methylprednisolone IV;   Drug: Rituximab IV
8 Recruiting Rotating Frame Relaxation Imaging in Patients With Multiple Sclerosis
Conditions: Multiple Sclerosis;   Multiple Sclerosis, Relapsing-Remitting;   Multiple Sclerosis, Chronic Progressive
Intervention: Other: Brain MRI
9 Completed China Betaferon Adherence, Coping and Nurse Support Study
Condition: Multiple Sclerosis, Chronic Progressive
Intervention: Drug: Interferon beta-1b (Betaseron, BAY86-5046)
10 Unknown  Evaluation of Efficiency of Ritalin in Multiple Sclerosis (MS) Patients
Conditions: Relapsing Remitting Multiple Sclerosis;   Multiple Sclerosis, Chronic Progressive
Intervention: Drug: Ritalin
11 Completed Safety Study of an Immunomodulating Microparticle to Treat Progressive Multiple Sclerosis
Conditions: Secondary Progressive Multiple Sclerosis;   Primary Progressive Multiple Sclerosis
Intervention: Biological: MIS416
12 Completed Sunphenon in Progressive Forms of Multiple Sclerosis
Condition: Multiple Sclerosis
Interventions: Drug: Sunphenon EGCG;   Drug: Placebo
13 Not yet recruiting Hydroxychloroquine in Primary Progressive Multiple Sclerosis
Condition: Multiple Sclerosis, Primary Progressive
Intervention: Drug: Hydroxychloroquine
14 Available Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Drug: Ocrelizumab
15 Active, not recruiting Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers
Condition: Multiple Sclerosis
Intervention: Drug: BG00012 (DMF) (Tecfidera®.)
16 Recruiting Mitochondrial Dysfunction and Disease Progression
Conditions: Clinically Isolated Syndrome;   Relapsing-Remitting Multiple Sclerosis;   Secondary Progressive Multiple Sclerosis;   Primary Progressive Multiple Sclerosis
Intervention:
17 Recruiting A Phase 1b, Open-label Study of Liothyronine in MS
Conditions: Multiple Sclerosis, Relapsing-Remitting;   Multiple Sclerosis, Secondary Progressive;   Multiple Sclerosis, Primary Progressive
Intervention: Drug: liothyronine
18 Active, not recruiting Autologous Mesenchymal Stromal Cells for Multiple Sclerosis
Conditions: Relapsing-Remitting Multiple Sclerosis;   Secondary Progressive Multiple Sclerosis
Interventions: Drug: XCEL-MC-ALPHA;   Drug: Placebo
19 Terminated BG00012 and Disability Progression in Secondary Progressive Multiple Sclerosis (SPMS)
Condition: Multiple Sclerosis, Secondary Progressive
Interventions: Drug: dimethyl fumarate;   Other: Placebo
20 Active, not recruiting Mechanistic Studies of Phase III Trial With BAF312 in Secondary Progressive Multiple Sclerosis
Condition: Secondary Progressive Multiple Sclerosis
Interventions: Procedure: Blood Draw;   Procedure: CSF collection by lumbar puncture (Optional)

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years